Gene
PML
PML is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (4), Actionable biomarkers (4), Trial mentions (753), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PML. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 6 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 69 of 8,738 | 0.79% | not measured | |
| 2025 | 45 of 8,875 | 0.51% | not measured | |
| 2024 | 66 of 8,597 | 0.77% | not measured | |
| 2023 | 45 of 8,275 | 0.54% | 3 of 11,460 | 0.03% |
| 2022 | 47 of 8,285 | 0.57% | 12 of 13,598 | 0.09% |
| 2021 | 59 of 8,692 | 0.68% | 10 of 15,045 | 0.07% |
| 2020 | 46 of 7,640 | 0.60% | 14 of 14,459 | 0.10% |
| 2019 | 41 of 7,300 | 0.56% | 10 of 12,159 | 0.08% |
| 2018 | 45 of 6,927 | 0.65% | 10 of 11,854 | 0.08% |
| 2017 | 44 of 6,558 | 0.67% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (4)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | June 17, 2010 |
| BD Transduction Laboratories | Reagent supplier | Clinical validation | 1 | June 17, 2010 |
| Santa Cruz Biotechnology | Reagent supplier | Clinical validation | 1 | June 17, 2010 |
| Thermo Scientific | Reagent supplier | Clinical validation | 1 | June 17, 2010 |
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PML-RARA fusion | All -trans Retinoic Acid (ATRA) | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| PML-RARA fusion | Volasertib | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| PML-RARA fusion | Arsenic Trioxide | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| PML-RARA fusion | All -trans Retinoic Acid (ATRA) | response-associated | acute promyelocytic leukemia | Cancer Genome Interpreter |
Trial mentions (753)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00300209 | Trial eligibility (AACT) |
| NCT04657094 | Trial eligibility (AACT) |
| NCT07860775 | Trial eligibility (AACT) |
| NCT01235572 | Trial eligibility (AACT) |
| NCT05672251 | Trial eligibility (AACT) |
Showing 5 of 753 trial mentions.
Target-disease associations (345)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Mouse knockout (IMPC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 345 associations.
Vendor sourcing (2,563)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3B Biotech Research | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Non-relapsing MS Pregnancy or lactation - Contraindication to receive cladribine or to continue anti-CD20 therapies according to local label - Inabilit... | View trial NCT06854094 |
| 3B Biotech Research | Trial collaborator | Mentioned in trial textTrial free-text mention | PML | View trial NCT06854094 |
| AGA Clinical Research Associates, LLC | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients who meet any of the following criteria will be excluded from study entry: * Abnormal MARSH score on enrollment histopathology * Elevated celiac... | View trial NCT02929316 |
| AGA Clinical Research Associates, LLC | Trial sponsor | Mentioned in trial textTrial free-text mention | PML | View trial NCT02929316 |
| ANRS, Emerging Infectious Diseases | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Permanent: * Hepatic cirrhosis * Serious psychiatric illness history * EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or mu... | View trial NCT01453192 |
Showing 5 of 2,563 sourcing records.
Trial-cited literature (148)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP seroincidence study): a cross-sectional, multicenter study. | Lancet regional health. Americas | 2023 | 45 |
| Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. | BMC cancer | 2023 | 29 |
| Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. | BMJ open | 2023 | 7 |
| Mechanics and functional consequences of nuclear deformations. | Nature reviews. Molecular cell biology | 2022 | 358 |
| APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. | Hepatology international | 2022 | 108 |
Showing 5 of 148 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.L217F | 1 | 2020 | PMID 32059085 |
| p.L218F | 1 | 2020 | PMID 32059085 |
Literature-extracted relations (37)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Arsenic Trioxide | Chemical | associate |
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. | 2021 |
| Arsenic Trioxide | Chemical | negative_correlate |
Molecular remission as a therapeutic objective in acute promyelocytic leukemia. | 2018 |
| Tretinoin | Chemical | negative_correlate |
Molecular remission as a therapeutic objective in acute promyelocytic leukemia. | 2018 |
| Tretinoin | Chemical | negative_correlate |
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. | 2015 |
| Arsenic Trioxide | Chemical | negative_correlate |
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. | 2015 |
Showing 5 of 37 relation assertions.
Organizations publishing (217)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 6 | 2003 to 2018 |
| Harvard Medical School | Academic | 6 | 2012 to 2021 |
| Helmholtz Association of German Research Centres | Government | 4 | 2015 to 2021 |
| Mass General Brigham | Hospital | 4 | 2012 to 2023 |
| Mayo Clinic | Hospital | 4 | 2011 to 2022 |
Showing 5 of 217 organizations.
Where PML appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
312 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.